235 related articles for article (PubMed ID: 24440911)
1. Multiple receptor tyrosine kinases converge on microRNA-134 to control KRAS, STAT5B, and glioblastoma.
Zhang Y; Kim J; Mueller AC; Dey B; Yang Y; Lee DH; Hachmann J; Finderle S; Park DM; Christensen J; Schiff D; Purow B; Dutta A; Abounader R
Cell Death Differ; 2014 May; 21(5):720-34. PubMed ID: 24440911
[TBL] [Abstract][Full Text] [Related]
2. Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers.
Ebi H; Corcoran RB; Singh A; Chen Z; Song Y; Lifshits E; Ryan DP; Meyerhardt JA; Benes C; Settleman J; Wong KK; Cantley LC; Engelman JA
J Clin Invest; 2011 Nov; 121(11):4311-21. PubMed ID: 21985784
[TBL] [Abstract][Full Text] [Related]
3. Coactivation of receptor tyrosine kinases affects the response of tumor cells to targeted therapies.
Stommel JM; Kimmelman AC; Ying H; Nabioullin R; Ponugoti AH; Wiedemeyer R; Stegh AH; Bradner JE; Ligon KL; Brennan C; Chin L; DePinho RA
Science; 2007 Oct; 318(5848):287-90. PubMed ID: 17872411
[TBL] [Abstract][Full Text] [Related]
4. miRNA-96 suppresses KRAS and functions as a tumor suppressor gene in pancreatic cancer.
Yu S; Lu Z; Liu C; Meng Y; Ma Y; Zhao W; Liu J; Yu J; Chen J
Cancer Res; 2010 Jul; 70(14):6015-25. PubMed ID: 20610624
[TBL] [Abstract][Full Text] [Related]
5. FRMD6 inhibits human glioblastoma growth and progression by negatively regulating activity of receptor tyrosine kinases.
Xu Y; Wang K; Yu Q
Oncotarget; 2016 Oct; 7(43):70080-70091. PubMed ID: 27661120
[TBL] [Abstract][Full Text] [Related]
6. Receptor Tyrosine Kinase Signaling and Targeting in Glioblastoma Multiforme.
Tilak M; Holborn J; New LA; Lalonde J; Jones N
Int J Mol Sci; 2021 Feb; 22(4):. PubMed ID: 33673213
[TBL] [Abstract][Full Text] [Related]
7. The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases.
Pillay V; Allaf L; Wilding AL; Donoghue JF; Court NW; Greenall SA; Scott AM; Johns TG
Neoplasia; 2009 May; 11(5):448-58, 2 p following 458. PubMed ID: 19412429
[TBL] [Abstract][Full Text] [Related]
8. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes.
Li Y; Guessous F; Zhang Y; Dipierro C; Kefas B; Johnson E; Marcinkiewicz L; Jiang J; Yang Y; Schmittgen TD; Lopes B; Schiff D; Purow B; Abounader R
Cancer Res; 2009 Oct; 69(19):7569-76. PubMed ID: 19773441
[TBL] [Abstract][Full Text] [Related]
9. MicroRNA-30b functions as a tumour suppressor in human colorectal cancer by targeting KRAS, PIK3CD and BCL2.
Liao WT; Ye YP; Zhang NJ; Li TT; Wang SY; Cui YM; Qi L; Wu P; Jiao HL; Xie YJ; Zhang C; Wang JX; Ding YQ
J Pathol; 2014 Mar; 232(4):415-27. PubMed ID: 24293274
[TBL] [Abstract][Full Text] [Related]
10. miR-218 opposes a critical RTK-HIF pathway in mesenchymal glioblastoma.
Mathew LK; Skuli N; Mucaj V; Lee SS; Zinn PO; Sathyan P; Imtiyaz HZ; Zhang Z; Davuluri RV; Rao S; Venneti S; Lal P; Lathia JD; Rich JN; Keith B; Minn AJ; Simon MC
Proc Natl Acad Sci U S A; 2014 Jan; 111(1):291-6. PubMed ID: 24368849
[TBL] [Abstract][Full Text] [Related]
11. Preclinical rationale for use of the clinically available multitargeted tyrosine kinase inhibitor crizotinib in ROS1-translocated lung cancer.
Yasuda H; de Figueiredo-Pontes LL; Kobayashi S; Costa DB
J Thorac Oncol; 2012 Jul; 7(7):1086-90. PubMed ID: 22617245
[TBL] [Abstract][Full Text] [Related]
12. miR-216b suppresses tumor growth and invasion by targeting KRAS in nasopharyngeal carcinoma.
Deng M; Tang H; Zhou Y; Zhou M; Xiong W; Zheng Y; Ye Q; Zeng X; Liao Q; Guo X; Li X; Ma J; Li G
J Cell Sci; 2011 Sep; 124(Pt 17):2997-3005. PubMed ID: 21878506
[TBL] [Abstract][Full Text] [Related]
13. MiR-920 and LSP1 co-regulate the growth and migration of glioblastoma cells by modulation of JAK2/STAT5 pathway.
Cong P; Hou HY; Wei W; Zhou Y; Yu XM
J Bioenerg Biomembr; 2020 Oct; 52(5):311-320. PubMed ID: 32770294
[TBL] [Abstract][Full Text] [Related]
14. Loss of EGFR signaling regulated miR-203 promotes prostate cancer bone metastasis and tyrosine kinase inhibitors resistance.
Siu MK; Abou-Kheir W; Yin JJ; Chang YS; Barrett B; Suau F; Casey O; Chen WY; Fang L; Hynes P; Hsieh YY; Liu YN; Huang J; Kelly K
Oncotarget; 2014 Jun; 5(11):3770-84. PubMed ID: 25004126
[TBL] [Abstract][Full Text] [Related]
15. Targeting HSP90 in ovarian cancers with multiple receptor tyrosine kinase coactivation.
Jiao Y; Ou W; Meng F; Zhou H; Wang A
Mol Cancer; 2011 Sep; 10():125. PubMed ID: 21962244
[TBL] [Abstract][Full Text] [Related]
16. Polo-like kinase 1 inhibition kills glioblastoma multiforme brain tumor cells in part through loss of SOX2 and delays tumor progression in mice.
Lee C; Fotovati A; Triscott J; Chen J; Venugopal C; Singhal A; Dunham C; Kerr JM; Verreault M; Yip S; Wakimoto H; Jones C; Jayanthan A; Narendran A; Singh SK; Dunn SE
Stem Cells; 2012 Jun; 30(6):1064-75. PubMed ID: 22415968
[TBL] [Abstract][Full Text] [Related]
17. Crizotinib and erlotinib inhibits growth of c-Met
Goodwin CR; Rath P; Oyinlade O; Lopez H; Mughal S; Xia S; Li Y; Kaur H; Zhou X; Ahmed AK; Ho S; Olivi A; Lal B
Clin Neurol Neurosurg; 2018 Aug; 171():26-33. PubMed ID: 29803091
[TBL] [Abstract][Full Text] [Related]
18. Activation of RAS family members confers resistance to ROS1 targeting drugs.
Cargnelutti M; Corso S; Pergolizzi M; Mévellec L; Aisner DL; Dziadziuszko R; Varella-Garcia M; Comoglio PM; Doebele RC; Vialard J; Giordano S
Oncotarget; 2015 Mar; 6(7):5182-94. PubMed ID: 25691052
[TBL] [Abstract][Full Text] [Related]
19. A novel berbamine derivative inhibits cell viability and induces apoptosis in cancer stem-like cells of human glioblastoma, via up-regulation of miRNA-4284 and JNK/AP-1 signaling.
Yang F; Nam S; Brown CE; Zhao R; Starr R; Ma Y; Xie J; Horne DA; Malkas LH; Jove R; Hickey RJ
PLoS One; 2014; 9(4):e94443. PubMed ID: 24732116
[TBL] [Abstract][Full Text] [Related]
20. Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells.
Hu J; Jo M; Cavenee WK; Furnari F; VandenBerg SR; Gonias SL
Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15984-9. PubMed ID: 21896743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]